Literature DB >> 10516850

Factors regulating the growth of metastatic cancer in bone.

B F Boyce1, T Yoneda, T A Guise.   

Abstract

Metastatic tumor cells can interfere directly with the function of bone cells involved in normal bone remodeling or indirectly by influencing the behavior of hematopoietic, stromal and other cells in bone marrow that interact with bone cells. Recent studies of metastatic cancer have revealed that tumor cells interact closely with vascular endothelial cells, basement membrane and bone marrow stromal cells through cell surface proteins or by releasing factors which affect the function of these cells. Bidirectional interaction between marrow cells and tumor cells can give the latter a selective advantage for growth in bone which can lead to the destruction of or to increased production of bone matrix. Understanding of the mechanisms involved in tumor metastasis and growth in bone has increased in recent years, and in this review we shall describe current knowledge of these mechanisms and of the predilection of certain types of cancers to metastasize to bone, their growth in the bone microenvironment and interactions between them and bone cells. Because metastatic breast cancer has been studied more than any other, we shall focus on it as a representative example, although the general principles apply to other types of cancer and to myeloma.

Entities:  

Mesh:

Year:  1999        PMID: 10516850     DOI: 10.1677/erc.0.0060333

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  31 in total

Review 1.  PTH and PTHrP effects on the skeleton.

Authors:  A C Karaplis; D Goltzman
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

Review 2.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

3.  Further evidence to support the melanocytic origin of MDA-MB-435.

Authors:  G Ellison; T Klinowska; R F R Westwood; E Docter; T French; J C Fox
Journal:  Mol Pathol       Date:  2002-10

4.  Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone.

Authors:  Olga Zolochevska; Jayne Ellis; Sangram Parelkar; Delphine Chan-Seng; Todd Emrick; Jingna Wei; Igor Patrikeev; Massoud Motamedi; Marxa L Figueiredo
Journal:  Hum Gene Ther       Date:  2013-11-06       Impact factor: 5.695

5.  Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.

Authors:  Longwei Qiao; Yuting Liang; Na Li; Xiaoxia Hu; Dongwei Luo; Junxia Gu; Yaojuan Lu; Qiping Zheng
Journal:  Int J Clin Exp Med       Date:  2015-03-15

6.  The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability.

Authors:  Hai Wang; Lin Tian; Jun Liu; Amit Goldstein; Igor Bado; Weijie Zhang; Benjamin R Arenkiel; Zonghai Li; Meng Yang; Shiyu Du; Hong Zhao; David R Rowley; Stephen T C Wong; Zbigniew Gugala; Xiang H-F Zhang
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

Review 7.  The botanical molecule p-hydroxycinnamic acid as a new osteogenic agent: insight into the treatment of cancer bone metastases.

Authors:  Masayoshi Yamaguchi
Journal:  Mol Cell Biochem       Date:  2016-08-30       Impact factor: 3.396

8.  Potential suppressive effects of gentian violet on human breast cancer MDA-MB-231 cells in vitro: Comparison with gemcitabine.

Authors:  Masayoshi Yamaguchi; Tomiyasu Murata
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967

Review 9.  More than the genes, the tumor microenvironment in neuroblastoma.

Authors:  Lucia Borriello; Robert C Seeger; Shahab Asgharzadeh; Yves A DeClerck
Journal:  Cancer Lett       Date:  2015-11-17       Impact factor: 8.679

Review 10.  Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases.

Authors:  Jeske J Smink; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2009-11-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.